Related Diseases: Corticobasal Degeneration, Progressive Supranuclear Palsy, Alzheimer's Disease
Related Pathways: Tauopathies, Protein Aggregation, Neuroinflammation
Related Proteins: Tau, 4R Tau, Neurofilament Light Chain
Related Biomarkers: CSF Biomarkers, Blood Biomarkers
Proteomics studies in corticobasal degeneration (CBD) have revealed distinctive molecular signatures in brain tissue and biofluids. These studies provide insights into the pathogenic mechanisms underlying this 4R tauopathy and help distinguish CBD from related neurodegenerative disorders.
A key study identified altered cerebrospinal fluid proteins in CBD patients compared to controls[1]. These findings help characterize the molecular landscape of CBD and identify potential biomarker candidates.
Large-scale network analysis of CSF proteome has identified molecular signatures in frontotemporal lobar degeneration spectrum disorders including CBD[2]:
Network-based proteomics has identified replicable molecular pathways and hub proteins that may serve as candidate biomarkers and therapeutic targets.
An early proteomic analysis using two-dimensional gel electrophoresis identified specific protein changes in CBD brain tissue[3]:
Upregulated Proteins:
Downregulated Proteins:
These proteins are involved in protein quality control, energy metabolism, and oxidative stress response—all pathways relevant to neurodegeneration.
Recent studies using sarkosyl fractionation have characterized the soluble and insoluble proteome in primary tauopathies[4]:
SORT1 (Sortilin-1) is highly insoluble in CBD and aggregates to different extents across tauopathies. ROCK1 and JAK2 show shifts in solubility for key signaling pathways.
ProPPr (Probe-dependent Proximity Profiling) analysis has identified tau aggregate-associated proteins in CBD[5]:
Common to All Tauopathies (229 proteins):
CBD-Specific Findings:
CBD brain tissue shows alterations in mitochondrial proteins involved in:
CSF and brain tissue proteomics consistently show:
CBD shows unique lysosomal protein insolubility patterns:
ECM alterations in CBD include:
| Feature | CBD | PSP | AD | PiD |
|---|---|---|---|---|
| 4R Tau | +++ | +++ | +/- | - |
| TDP-43 | ++ | - | + | - |
| Synaptic Loss | ++ | ++ | +++ | + |
| Lysosomal Changes | ++ | + | + | + |
| Similarity to CBD | — | Moderate | Low | High |
CBD and PiD show the greatest proteomic similarity, while PSP is most divergent[4:1].
| Protein | Change | Pathway | Reference |
|---|---|---|---|
| PIMT | Upregulated | Protein repair | [3:1] |
| Cofilin 1 | Upregulated | Cytoskeleton | [3:2] |
| UCH-L1 | Downregulated | Protein degradation | [3:3] |
| PRDX5 | Downregulated | Oxidative stress | [3:4] |
| SORT1 | Highly insoluble | Lysosomal/ECM | [4:2] |
| FTL | Insoluble (specific) | Iron metabolism | [5:1] |
| VPS35 | Associated | Retromer | [5:2] |
| LAMP2 | Associated | Lysosomal | [5:3] |
While direct proteomic profiling of CBD brain tissue and CSF provides detailed mechanistic insights, blood-based proteomics offers minimally invasive biomarker candidates for diagnosis and disease monitoring.
Emerging studies on plasma extracellular vesicles (EVs) provide cell-type-specific proteomic signatures:
| Biomarker | Blood | CSF | Brain Tissue |
|---|---|---|---|
| NfL | +++ (elevated) | +++ (elevated) | N/A |
| p-tau | ++ (mildly elevated) | +++ (elevated) | +++ (aggregated) |
| GFAP | ++ (elevated) | + (elevated) | +++ (reactive astrocytes) |
| Synaptic proteins | + (decreased) | ++ (decreased) | +++ (lost) |
Large-scale plasma proteomics studies in neurodegenerative diseases have identified:
These findings suggest systemic changes accompanying CNS pathology in CBD.
The proteomic signatures in CBD suggest several therapeutic targets:
Paslawski W, Bergström S, Zhang X, Remnestål J, He Y, Boxer A, Månberg A, Nilsson P, Svenningsson P. Cerebrospinal Fluid Proteins Altered in Corticobasal Degeneration. Mov Disord. 2021. ↩︎
Saloner R, Staffaroni AM, Dammer EB, Johnson ECG, et al. Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration. Nat Neurosci. 2025. ↩︎
Chen W, Ji J, Ru B. 'Proteomic analysis of corticobasal degeneration: a case study of corticobasal degeneration at the proteome level'. J Neural Transm. 2005. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Kavanagh T, Balcomb K, Trgovcevic S, Nementzik L, et al. Differences in the soluble and insoluble proteome between primary tauopathies. Acta Neuropathol. 2025. ↩︎ ↩︎ ↩︎
Morderer D, Wren MC, Liu F, Kouri N, et al. Probe-dependent Proximity Profiling (ProPPr) Uncovers Similarities and Differences in Phospho-Tau-Associated Proteomes Between Tauopathies. Brain. 2025. ↩︎ ↩︎ ↩︎ ↩︎
Default. Plasma Neurofilament Light Chain in Corticobasal Degeneration. Mov Disord. 2024. ↩︎